Palliative Radiotherapy Given Concurrently or Within 4 Weeks of Initiation of Immunotherapy is Associated with Sustained Clinical Response to Immune Checkpoint Inhibitors in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC)

Whitaker, R. M., Gillaspie, E. A., Horn, L., & Osmundson, E. C. (2019). Palliative Radiotherapy Given Concurrently or Within 4 Weeks of Initiation of Immunotherapy is Associated with Sustained Clinical Response to Immune Checkpoint Inhibitors in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology*Biology*Physics, 105(1), E538. https://doi.org/10.1016/j.ijrobp.2019.06.2454